The Centers for Medicare and Medicaid Services announced Tuesday that it will let Biden-era Medicare Part D premium subsidies expire at the end of 2026, a move affecting roughly 25 million Americans with standalone drug plans.

CMS Administrator Dr. Mehmet Oz framed the decision as a market correction, calling the subsidy program a "bailout" that enriched insurance companies rather than the seniors it was supposed to help. The subsidies, which kept monthly premiums artificially low for Part D enrollees, will not be renewed for 2027. Enrollees will begin seeing new pricing details in mid- to late-September, when CMS expects to release individual cost breakdowns.

The Hill reported that the 2027 national average monthly bid amount, the figure insurers charge CMS per enrollee, will be $296.05, with a base beneficiary premium of $41.33. Those numbers will replace whatever enrollees currently pay under the subsidized structure, though CMS has not published the current-year figures for direct comparison.

Oz says most enrollees face less than $10 in added monthly costs

Oz posted the announcement on X, pushing back against the idea that ending the subsidies would hammer seniors on fixed incomes. He argued the opposite: that the program had propped up insurer profits while giving enrollees a false sense of savings.

In his post, Oz laid out the administration's case:

"We are stabilizing the market so this bailout is no longer needed. Premiums will go up by less than $10 for most Medicare recipients, with many even seeing LOWER premiums."

He followed that with a broader promise about drug costs:

"Every Medicare beneficiary still has access to low-cost plans, and we will continue to lower prescription drug prices for every American patient, from more MFN deals to our policy giving seniors access to GLP-1s for $50 a month."

The reference to "MFN deals", most-favored-nation pricing, a mechanism designed to tie what the U.S. pays for drugs to the lower prices charged in other countries, signals the administration intends to keep pressing pharmaceutical companies on pricing even as it removes the premium subsidy backstop.

Biden restructured Part D with a $2,000 out-of-pocket cap and drug-price negotiations

The subsidy program being wound down was restructured under former President Biden. That restructuring introduced a $2,000 annual cap on out-of-pocket prescription drug spending for Part D enrollees and, for the first time, permitted Medicare to negotiate prices directly on certain high-cost Part D drugs. The premium subsidies were layered on top of those changes, keeping monthly costs lower during the transition.

The Trump administration's position is that the subsidies served as a cushion for insurers adjusting to the new rules, not a permanent benefit for patients. With insurers now operating under the restructured framework, CMS argues the cushion is no longer justified. The administration has taken a similar posture toward rooting out waste in federal health programs, including cracking down on fraud across Medicare and Medicaid.

But the decision leaves several questions unanswered. CMS has not disclosed what enrollees currently pay in premiums, making it difficult to verify the "less than $10" claim independently. The agency also has not specified how many of the roughly 25 million standalone Part D enrollees, a figure attributed to Reuters, actually receive the subsidy. And the exact mechanism the administration will use to end the program, whether through executive action, a regulatory change, or simply declining to renew it, remains unclear.

25 million enrollees wait for September cost details

The majority of standalone Part D enrollees are seniors or people with disabilities. For them, the gap between the announcement and the September cost release creates a window of uncertainty. They know the subsidies are going away. They do not yet know what their individual premiums will look like.

The administration's broader approach to federal health care spending reflects a pattern of tightening oversight and cutting programs it views as misaligned with their stated purpose. That same instinct has driven actions across agencies, from DOJ subpoenas targeting hospital practices to CMS's own efforts to rein in insurer subsidies.

Oz's framing puts the burden of proof on critics. If premiums rise modestly, under $10 a month for most, as he claims, the move looks like a sensible correction that strips a subsidy from corporations that didn't need it. If premiums jump significantly for vulnerable enrollees, the administration will own that outcome heading into 2027.

The September cost release will be the first real test. Until then, the administration is asking 25 million Americans to take its word that ending the subsidy won't cost them much, and that the real beneficiaries of the program were never patients in the first place.

When the government tells you a program meant for seniors was really a handout to insurers, the least it can do is show the math before the checks stop.